Search research articles
Contact Us
Filters
Showing results (1-10 of 87) with videos related to
Page
of 9
Sort By:
Annals of Hematology
|
March 28, 2015
A review of the European LeukemiaNet recommendations for the management of CML
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Nature Reviews. Clinical Oncology
|
November 3, 2016
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Cancer Treatment Reviews
|
August 16, 2011
Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Aging
|
December 29, 2011
Imatinib in chronic myeloid leukemia elderly patients
Gabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.
Expert Review of Hematology
|
March 27, 2014
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Hemasphere
|
March 21, 2022
Current treatment approaches in CML
Fausto Castagnetti, Gabriele Gugliotta, Simona Soverini, et al.
Italian Journal of Dermatology and Venereology
|
January 30, 2024
Psoriasis: a new adverse event of ibrutinib
Luca Rapparini, Alice Massi, Carlotta Baraldi, et al.
Best Practice & Research. Clinical Haematology
|
December 5, 2009
Response definitions and European Leukemianet Management recommendations
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Critical Reviews in Oncology/Hematology
|
May 14, 2011
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
January 24, 2014
Treatment recommendations for chronic myeloid leukemia
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 87) with videos related to
Sort By:
Page
of 9
Annals of Hematology
|
March 28, 2015
A review of the European LeukemiaNet recommendations for the management of CML
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Nature Reviews. Clinical Oncology
|
November 3, 2016
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Cancer Treatment Reviews
|
August 16, 2011
Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Aging
|
December 29, 2011
Imatinib in chronic myeloid leukemia elderly patients
Gabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.
Expert Review of Hematology
|
March 27, 2014
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Hemasphere
|
March 21, 2022
Current treatment approaches in CML
Fausto Castagnetti, Gabriele Gugliotta, Simona Soverini, et al.
Italian Journal of Dermatology and Venereology
|
January 30, 2024
Psoriasis: a new adverse event of ibrutinib
Luca Rapparini, Alice Massi, Carlotta Baraldi, et al.
Best Practice & Research. Clinical Haematology
|
December 5, 2009
Response definitions and European Leukemianet Management recommendations
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Critical Reviews in Oncology/Hematology
|
May 14, 2011
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Mediterranean Journal of Hematology and Infectious Diseases
|
January 24, 2014
Treatment recommendations for chronic myeloid leukemia
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Page
of 9